Literature DB >> 287189

D-penicillamine: biochemical, metabolic and pharmacological aspects.

R J van de Stadt, A O Muijsers, A M Henrichs, J K van der Korst.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 287189     DOI: 10.3109/03009747909108229

Source DB:  PubMed          Journal:  Scand J Rheumatol Suppl        ISSN: 0301-3847


× No keyword cloud information.
  7 in total

1.  Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine.

Authors:  T Matsubara; R Saura; K Hirohata; M Ziff
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

2.  Serum SH reactivity: a simple assessment of D-penicillamine absorption?

Authors:  N D Hall; D R Blake; G J Alexander; C Vaisey; P A Bacon
Journal:  Rheumatol Int       Date:  1981       Impact factor: 2.631

Review 3.  Clinical pharmacokinetics of D-penicillamine.

Authors:  P Netter; B Bannwarth; P Péré; A Nicolas
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

4.  Effects of D-penicillamine on mononuclear cells in vitro.

Authors:  J L Riestra; M Harth; A Rodriguez; C L Larrea
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

5.  Inhibition of human helper T cell function in vitro by D-penicillamine and CuSO4.

Authors:  P E Lipsky; M Ziff
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

6.  D-penicillamine metabolism in an in-vivo model of inflamed synovium.

Authors:  D A Joyce; M J Forrest; P M Brooks
Journal:  Agents Actions       Date:  1988-12

7.  D-Penicillamine Reveals the Amelioration of Seizure-Induced Neuronal Injury via Inhibiting Aqp11-Dependent Ferroptosis.

Authors:  Nan Yang; Kai Zhang; Qi-Wen Guan; Zhao-Jun Wang; Kang-Ni Chen; Xiao-Yuan Mao
Journal:  Antioxidants (Basel)       Date:  2022-08-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.